Total Payments
$137,944
2023 Payments
$108,206
Companies
15
Transactions
92
Payment Breakdown by Category
Research$118,304 (85.8%)
Other$9,440 (6.8%)
Travel$3,758 (2.7%)
Consulting$3,600 (2.6%)
Food & Beverage$2,841 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $118,304 | 36 | 85.8% |
| Honoraria | $9,440 | 5 | 6.8% |
| Travel and Lodging | $3,758 | 15 | 2.7% |
| Consulting Fee | $3,600 | 2 | 2.6% |
| Food and Beverage | $2,841 | 34 | 2.1% |
Payments by Type
Research
$118,304
36 transactions
General
$19,640
56 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $103,662 | 9 | $0 (2023) |
| Lundbeck LLC | $11,138 | 8 | $0 (2021) |
| Eli Lilly and Company | $10,222 | 8 | $0 (2023) |
| Allergan, Inc. | $2,973 | 17 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $2,164 | 7 | $0 (2017) |
| H. Lundbeck A S | $2,040 | 1 | $0 (2021) |
| Sage Therapeutics, Inc. | $1,988 | 11 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,731 | 9 | $0 (2018) |
| Alnylam Pharmaceuticals Inc. | $832.36 | 8 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $798.84 | 9 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $108,206 | 29 | PFIZER INC. ($103,298) |
| 2022 | $4,956 | 5 | Eli Lilly and Company ($4,782) |
| 2021 | $6,990 | 6 | Eli Lilly and Company ($2,525) |
| 2020 | $5,215 | 11 | Lundbeck LLC ($3,600) |
| 2019 | $6,203 | 9 | Lundbeck LLC ($5,538) |
| 2018 | $1,439 | 13 | Allergan Inc. ($1,184) |
| 2017 | $4,936 | 19 | Regeneron Pharmaceuticals, Inc. ($2,164) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $12,184.28 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $10,142.18 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/26/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $4,642.50 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $9,547.24 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $2,940.40 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $48,591.72 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $4,350.10 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 06/11/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $632.76 | General |
| 06/11/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $72.00 | General |
| 06/11/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $30.00 | General |
| 06/11/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $15.36 | General |
| 06/10/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 06/10/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 06/10/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $37.50 | General |
| 06/10/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $37.50 | General |
| 06/09/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $798.82 | General |
| 06/09/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 06/09/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $113.89 | General |
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $10,899.97 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 03/27/2023 | Eli Lilly and Company | — | — | In-kind items and services | $205.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 03/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,882.14 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 01/30/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $261.01 | General |
| 01/30/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $196.96 | General |
| 01/30/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $130.68 | General |
| 01/30/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $87.12 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $103,298 | 8 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $5,629 | 2 |
| A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Regeneron Pharmaceuticals, Inc. | $2,164 | 7 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,975 | 3 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $1,882 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder | Teva Pharmaceuticals USA, Inc. | $764.07 | 7 |
| Phase IIA US POP w SOD 3125-201-002 | Allergan Inc. | $607.33 | 2 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $536.00 | 2 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $531.00 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $205.00 | 1 |
About Dr. Lora Mcgill, M.D
Dr. Lora Mcgill, M.D is a Neurology healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1891995213.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lora Mcgill, M.D has received a total of $137,944 in payments from pharmaceutical and medical device companies, with $108,206 received in 2023. These payments were reported across 92 transactions from 15 companies. The most common payment nature is "" ($118,304).
Ad
Practice Information
- Specialty Neurology
- Location Memphis, TN
- Active Since 07/23/2007
- Last Updated 07/23/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891995213
Products in Payments
- ZAVZPRET (Drug) $103,298
- VYEPTI (Biological) $4,040
- CNP520 (Drug) $946.83
- AJOVY (Biological) $786.74
- BOTOX (Biological) $425.03
- EUCRISA (Drug) $363.50
- FREESTYLE LIBRE (Device) $159.78
- BOTOX (Drug) $116.60
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Memphis
Dr. Lucas Elijovich, Md, MD
Neurology — Payments: $467,370
Neurology $467,370
Dr. Mark Ledoux, Md, MD
Neurology — Payments: $425,881
Neurology $425,881
Tulio Bertorini, Md, MD
Neurology — Payments: $262,872
Neurology $262,872
Rozita Khalili, Md, MD
Neurology — Payments: $90,621
Neurology $90,621
Michael Jacewicz, Md, MD
Neurology — Payments: $55,440
Neurology $55,440
Michael Levin, M.d, M.D
Neurology — Payments: $37,188
Neurology $37,188